Treatment outcomes of endogenous fungal endophthalmitis

Current Opinion in Ophthalmology

Volumn 9, Issue 3, 1998, Pages 66-70

  Smiddy, William E ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE;

CANDIDA ALBICANS; CHOROIDITIS; ENDOPHTHALMITIS; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; MYCOSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT OUTCOME; VISUAL ACUITY; VITRECTOMY;

ANTIFUNGAL AGENTS; CANDIDIASIS; ENDOPHTHALMITIS; EYE INFECTIONS, FUNGAL; HUMANS; TREATMENT OUTCOME; VITRECTOMY;

EID: 0031872845     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-199806000-00012     Document Type: Short Survey

References (24)

1. Brod RD, Flynn HW Jr, Clarkson JG, et al: Endogenous Candida endophthalmitis: management without intravenous amphotericin B. Ophthalmology 1990, 97:666-674.
2. Essman JF, Flynn HW Jr, Smiddy WE, et al: Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis. Ophthalmic Surg 1997, 28:185-194. This newest and largest review of a 10-year experience at one institution establishes numerous demographic and clinical information regarding the presentation, time course, and results of treatment of endogenous fungal endophthalmitis. It establishes the lower incidence of fungal endophthalmitis caused by non-Candida spp.
3. Brod RD, Clarkson JG, Flynn HW Jr, et al: Endogenous fungal endophthalmitis. In Duane's Clinical Ophthalmology. Edited by Tasman, W. Philadelphia: JB Lippincott; 1994:14-16.
4. Kostick DA, Foster RE, Lowder CY, et al: Endogenous endophthalmitis caused by Candida albicans in a healthy woman. Am J Ophthalmol 1992, 113:593-595.
5. Christmas N, Smiddy WE: Vitrectomy and systemic fluconazole for treatment of endogenous fungal endophthalmitis. Ophthalmic Surg Lasers 1996, 27:1012-1018. This series of six eyes in five patients is important for establishing the role of treatment without intravitreal amphotericin. It emphasizes the good results that can be obtained with only vitrectomy and follow-up of oral fluconazole. Excellent visual acuity was obtained in all patients except one, in which the chorioretinitis emanated from the center of the fovea. This paper also establishes that this entity may occur in patients who are not immunocompromised but who have had recent surgery.
6. Samiy N, D'Amico DJ: Endogenous fungal endophthalmitis. Int Ophthalmol Clin 1996, 36:142-162. This is an excellent review of all forms of endogenous fungal endophthalmitis. It is an excellent source text for citations of the rare forms of endogenous fungal endophthalmitis.
7. Donahue SP, Greven CM, Zuraleff JJ, et al: Intraocular candidiasis in patients with candidemia. Ophthalmology 1994, 101:1302-1309.
8. Parke DW II, Jones DB, Gentry LO: Endogenous endophthalmitis among patients with candidemia. Ophthalmology 1982, 89:789-796.
9. Bross J, Talbot GH, Maislin G, et al: Risk factors for nosocomial candidemia: a case control study in adults without leukemia. Am J Med 1989, 87:614-620.
10. Brooks RG: Prospective study of Candida endophthalmltis in hospitalized patients with candidemia. Arch Intern Med 1989, 149:2226-2228.
11. Montgomerie JZ, Edwards JE: Association of infection due to Candida albicans with intravenous hyperalimentation. J Infect Dis 1978, 137:197-201.
12. Enzenauer RW, Calderwood S, Levin AV, et al: Screening of fungal endophthalmitis in children at risk. Pediatrics 1992, 90:451-457.
13. Snip RC, Michels RG: Pars plana vitrectomy in the management of endogenous Candida endophthalmitis. Am J Ophthalmol 1976, 82:699-704.
14. Axelrod AJ, Peyman GA, Apple DJ: Toxicity of intravitreal injection of amphotericin B. Am J Ophthalmol 1973, 76:578-583.
15. Sovi EN, Green WR: Intravitreal amphotericin B toxicity. Am J Ophthalmol 1974, 78:77-81.
16. O'Day DM, Foulds G, Williams TE, et al: Ocular uptake of fluconazole following oral administration. Arch Ophthalmol 1990, 108:1006-1008.
17. Savani DV, Perfect JR, Lobo LM, Durack DT: Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother 1987, 31:6-10.
18. Henderson T, Irfan S: Bilateral endogenous Candida endophthalmitis and chorioretinitis following toxic megacolon. Eye 1996, 10:755-757.
19. Borne MJ, Elliott JH, O'Day DM: Ocular fluconazole treatment of Candida parapsilosis endophthalmitis after failed intravitreal amphotericin B. Arch Ophthalmol 1993, 111:1326-1337.
20. Luthell JK, Wan WL, Kubak BM, et al: Treatment of ocular fungal infections with oral fluconazole. Am J Ophthalmol 1995, 119:477-481.
21. Laatikainen L, Touminen M, von Dickhoff K: Treatment of endogenous fungal endophthalmitis with systemic fluconazole with or without vitrectomy. Am J Ophthalmol 1992, 113:205-207.
22. Nomura J, Ruskin J: Failure of therapy with fluconazole for candidal endophthalmitis. Clin Infect Dis 1993, 17:888-889.
23. Coats ML, Peyman GA: Intravitreal corticosteroids in the treatment of exogenous fungal endophthalmitis. Retina 1992, 12:46-51
24. Naoi N, Sanada A: Effect of vitrectomy or epiretinal membrane after endogenous fungal endophthalmitis. Jpn J Ophthalmol 1996, 40:434-438. This article specifically addresses the fact that vitrectomy for epiretinal membrane after the treatment of endogenous fungal endophthalmitis does lead to some improvement in vision. The experience is in only three cases but emphasizes the importance of not forgetting this therapeutic option after the treatment of the acute infection. Actually, much of this can be treated concomitantly with the vitrectomy for treatment of the acute infection.